Harmful impact of EU clinical trials directiveBMJ 2006; 332 doi: https://doi.org/10.1136/bmj.332.7540.501 (Published 02 March 2006) Cite this as: BMJ 2006;332:501
- Akseli Hemminki, group leader ([email protected]),
- Pirkko-Liisa Kellokumpu-Lehtinen, professor of radiotherapy and oncology ([email protected])
- Cancer Gene Therapy Group, University of Helsinki and Department of Oncology, Helsinki University Central Hospital, FIN-00014 Finland
- Tampere University Hospital, Tampere, FIN-33521 Finland
Innovative clinical and translational research, instigated and conducted by motivated physician-scientists, has had an important part in the development of modern oncology. For example, adjuvant treatments for breast and colorectal cancer, shown in randomised trials to be effective in preventing recurrence, have been developed and tested through research performed largely by academic clinicians.1–3 Similarly, such clinicians have been responsible for researching, developing, and introducing sentinel node biopsy and breast conserving surgery, which have reduced morbidity for many hundreds of thousands of women.4 5 Yet investigator initiated academic clinical research is under threat—ironically, from a European Union directive that is aimed at protecting patients and improving research standards.
The official goals of the EU clinical trials directive, implemented in 2004,6 were to improve the protection of patients and the reliability of research reporting and to harmonise and increase the competitiveness of European clinical research. The responsibilities of the research sponsor were increased significantly, and at the outset many investigators were worried that that the labour intensive, bureaucratic, and expensive endeavour of running a clinical trial would become worse.7 In particular, academic researchers …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial